Search Results for: LAM Therapeutics Announces Progress of
Articles
December 6, 2017
LAM Therapeutics Announces Progress of its Clinical Portfolio With FDA Clearance December 6, 2017
LAM Therapeutics, a 4Catalyzer company, advanced its clinical portfolio with the US FDA clearance of LAM’s Investigational New Drug (IND) application...
March 11, 2024
Monte Rosa Therapeutics Announces Initiation of IND Enabling Studies for First-in-Class NEK7 Directed Molecular Glue Degrader & NLRP3/IL-1β Pathway Inhibitor March 11, 2024
Monte Rosa Therapeutics, Inc. recently announced a novel development candidate, MRT-8102, a potent, highly selective and orally bioavailable NIMA related...
March 4, 2024
Indaptus Therapeutics Announces Positive Results From Second Cohort of Phase 1 Trial; Company Initiates Multi-Dose Cohort March 4, 2024
Indaptus Therapeutics, Inc. recently announced positive results from the second cohort of its Phase 1 INDP-D101 trial. Patients continue to...
February 26, 2024
Biora Therapeutics Announces Successful Completion of Single-Ascending Dose Cohorts of Phase 1 Clinical Study of BT-600 February 26, 2024
Biora Therapeutics, Inc. recently announced completion of the single-ascending dose (SAD) cohorts for its Phase 1, first-in-human clinical study of...
February 26, 2024
Tenaya Therapeutics Announces Preclinical HDAC6 Inhibitor Data for Heart Failure With Preserved Ejection Fraction February 26, 2024
Tenaya Therapeutics, Inc. recently announced the publication of preclinical research related to Tenaya’s small molecule inhibitors of histone deacetylase 6...
February 21, 2024
Vaccinex Announces Multiple New Agreements for Access to ActivMAb Antigen Virus Technology February 21, 2024
Vaccinex, Inc. recently announced it has entered into eight new antibody discovery agreements integrating use of its proprietary ActivMAb platform...
January 16, 2024
Coya Therapeutics Announces Pipeline Expansion of COYA 302 to Include Frontotemporal Dementia & Parkinson’s Disease in Addition to Amyotrophic Lateral Sclerosis January 16, 2024
Coya Therapeutics, Inc. recently announced it is expanding its pipeline in neurodegenerative conditions for COYA 302 beyond ALS to include...
January 15, 2024
ExeVir Bio Announces Positive Virus Neutralization Data for XVR012 Against Emerging COVID-19 Omicron Variants January 15, 2024
ExeVir Bio recently announced new data demonstrating that its antibodies are highly potent in neutralizing currently circulating COVID-19 Omicron variants....
January 8, 2024
Artelo Biosciences Announces Selection of Worldwide Clinical Trials as CRO to Support First-in-Human Study January 8, 2024
Artelo Biosciences, Inc. recently announced it has selected Worldwide Clinical Trials to support the its planned Phase 1 trial with...
January 4, 2024
Sitryx Announces Collaboration Partner Lilly Has Commenced Phase 1 Study of SIT-011 for Chronic Autoimmune & Inflammatory Diseases January 4, 2024
Sitryx Therapeutics recently announced Eli Lilly & Company has commenced a Phase 1 first-in-human study of SIT-011, a post-translational modification modulator program for chronic autoimmune and….
January 2, 2024
Avenue Therapeutics Announces Completion of Enrollment in Phase 1b/2a Clinical Trial for the Treatment of Spinal & Bulbar Muscular Atrophy January 2, 2024
Avenue Therapeutics, Inc. recently announced all patients have been enrolled in the Phase 1b/2a clinical trial of AJ201 for the...
December 11, 2023
Biora Therapeutics Announces New Research Collaboration for the BioJet Systemic Oral Delivery Platform December 11, 2023
Biora Therapeutics, Inc. recently announced a new research collaboration with a large pharmaceutical company for its BioJet Systemic Oral Delivery Platform. The new agreement provides funding….
November 1, 2023
Sitryx Announces Partner Eli Lilly & Company Exercises Option to SIT-011 for Chronic Autoimmune & Inflammatory Diseases November 1, 2023
Sitryx Therapeutics recently announced Eli Lilly & Company has exercised its option to progress SIT-011. Lilly will now lead further development and commercialization of the Phase 1 ready….
June 29, 2023
Urica Therapeutics Announces Topline Data From Phase 1 Clinical Trial Evaluating Dotinurad in Healthy Volunteers in the US June 29, 2023
Urica Therapeutics, Inc. recently announced topline data from the Phase 1 clinical trial evaluating dotinurad in healthy volunteers in the...
June 6, 2023
European Patent Office to Grant ZyVersa Therapeutics’ Patent Application for Cholesterol Transport Mediator for Use in Patients With Diabetic Nephropathy/Diabetic Kidney Disease June 6, 2023
ZyVersa Therapeutics, Inc. recently announces the European Patent Office has issued a “Notice of Intention to Grant” ZyVersa’s patent application...
June 6, 2023
Anavex Life Sciences Announces Completion of Phase 2/3 Rett Syndrome Clinical Trial June 6, 2023
Anavex Life Sciences Corp. recently announced the completion of dosing of all participants of the placebo-controlled EXCELLENCE Phase 2/3 study...
June 5, 2023
Synlogic Announces Initiation of Synpheny-3 Global, Pivotal Phase 3 Study Evaluating SYNB1934 for Treatment of Phenylketonuria June 5, 2023
Synlogic, Inc. recently announced the initiation of Synpheny-3, a global, pivotal Phase 3 study evaluating the efficacy and safety of...
April 24, 2023
Aevitas Therapeutics Announces Asset Purchase Agreement With 4D Molecular Therapeutics April 24, 2023
Aevitas Therapeutics, Inc. and 4D Molecular Therapeutics recently announced the execution of an asset purchase agreement for 4DMT to acquire...
April 5, 2023
AI Therapeutics Announces Positive Results From Phase 2a Biomarker-Driven Trial of AIT-101 in Patients with C9ORF72 Amyotrophic Lateral Sclerosis April 5, 2023
AI Therapeutics, Inc. recently announced positive results from a Phase 2a clinical trial of AIT-101 (LAM-002A) in patients with C9ORF72...
April 3, 2023
INFLAMMASOME INHIBITORS - 21st Century Miracle Drugs: Spotlight on Clinical NLRP3 Inflammasome Inhibitors April 3, 2023
Bryan Oronsky, PhD, says traditionally, pharmaceutical development is based on the “magic bullet” concept of “one drug, one target, one disease.” However, with the growing realization that chronic inflammation lies at the center of many, if not all, diseases, it is possible to envision inflammasome inhibitors, which reduce or prevent inflammation, as near-universal treatment panaceas.
